Abstract
Metadichol, a nanoemulsion of long-chain lipid alcohols, demonstrates a unique capacity to modulate the expression of the entire (KLF) transcription factor family (KLF1–KLF18) in human peripheral blood mononuclear cells (PBMCs) in a concentration-dependent manner. Using qRT-PCR and Western blot techniques, at 1 ng/ml, Metadichol downregulated 14 of 18 KLFs while selectively upregulating KLF4, KLF15, KLF17, and KLF18—factors often implicated in tumor suppression or context-dependent cancer regulation. Lower and higher concentrations produced distinct, biphasic expression patterns, indicating complex dose-dependent regulatory mechanisms. Beyond the KLF family, previous work has shown that metadichol influences interconnected signaling networks involving nuclear receptors, sirtuins, Toll-like receptors, circadian genes, and key tumor suppressors such as TP53 and Klotho. Network analysis suggests that this broad-spectrum modulation may overcome compensatory mechanisms within cancer cells, offering synergistic antitumor effects. The scope of this paper is to comprehensively analyze Metadichol and its dose-dependent regulation of KLFs and related pathways, while the purpose is to establish Metadichol as a multitarget anticancer agent capable of overcoming compensatory mechanisms in cancer cells, with potential applications in other diseases driven by transcriptional dysregulation. By simultaneously targeting multiple pathways, Metadichol offers a novel integrative approach to enhance therapeutic efficacy compared to single-pathway interventions.